المؤلفون: Avgerinos, Efthimios D., Kostopanagiotou, Georgia, Kostopanagiotou, Kostas, Kopanakis, Nikolaos, Andreadou, Ioanna, Lekka, Marilena, Nakos, George, Smyrniotis, Vasilios

المصدر: Journal of Surgical Research ; volume 246, page 629 ; ISSN 0022-4804

مصطلحات موضوعية: Surgery

الإتاحة: https://doi.org/10.1016/j.jss.2017.11.042Test
https://api.elsevier.com/content/article/PII:S002248041730731X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S002248041730731X?httpAccept=text/plainTest

المؤلفون: Spiliotis, John, Kalles, Vasileios, Kyriazanos, Ioannis, Terra, Alexios, Prodromidou, Anastasia, Raptis, Apostolos, Kopanakis, Nikolaos, Christopoulou, Athina

المصدر: Pleura and Peritoneum ; volume 4, issue 4 ; ISSN 2364-768X 2364-7671

الوصف: Background Combining cytoreductive surgery (CRS) with Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) can benefit patients with peritoneal metastasis from colorectal cancer. The present study evaluates the small bowel subset of the Peritoneal Cancer Index (Small-Bowel-PCI score (SB-PCI), min-max 0–12) as a prognostic factor in such patients. Methods We retrospectively analyzed patients that underwent CRS and HIPEC for recurrent colorectal cancer with peritoneal metastasis. Patient characteristics, procedure details, and clinical outcomes were evaluated. Results Eighty patients were included. The mean intraoperative PCI-score was 16.8, with a mean SB-PCI score of 5.9. CC0/1 was achieved in 62/80 patients. The mean follow-up period was 26.3 months. Univariate regression analysis showed that the ECOG status, the presence of severe complications, the HIPEC regimen (oxaliplatin vs. mitomycin-C), the PCI score, the SB-PCI score and the completeness of cytoreduction correlated significantly with overall survival. In multivariate analysis, the SB-PCI and CC score were identified as independent prognostic factors of survival. When the SB-PCI was stratified in three groups (0–4, 5–8 and 9–12), Kaplan–Meier curve analysis showed significant difference in survival (p<0.001). Conclusions The SB-PCI correlates with overall survival in patients with peritoneal metastases secondary to colorectal cancer in this retrospective cohort. Its use should be validated in prospective patient series.

الإتاحة: https://doi.org/10.1515/pp-2019-0018Test
https://www.degruyter.com/view/journals/pp/4/4/article-20190018.xmlTest

المؤلفون: Cornali, Tommaso, Sammartino, Paolo, Kopanakis, Nikolaos, Christopoulou, Athina, Framarino dei Malatesta, Marialuisa, Efstathiou, Elias, Spagnoli, Alessandra, Ciardi, Antonio, Biacchi, Daniele, Spiliotis, John

المساهمون: Cornali, Tommaso, Sammartino, Paolo, Kopanakis, Nikolao, Christopoulou, Athina, Framarino dei Malatesta, Marialuisa, Efstathiou, Elia, Spagnoli, Alessandra, Ciardi, Antonio, Biacchi, Daniele, Spiliotis, John

مصطلحات موضوعية: Surgery, oncology, endometrial cancer

الوصف: Background: More information is needed for selection of patients with peritoneal metastases from endometrial cancer (EC) to undergo cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). Methods: This study analyzed clinical, pathologic, and treatment data for patients with peritoneal metastases from EC who underwent CRS plus HIPEC at two tertiary centers. The outcome measures were morbidity, overall survival (OS), and progression-free survival (PFS) during a median 5year follow-up period. Uni- and multivariate analyses were performed to identify significant factors related to outcome. Results: A total of 33 patients met the inclusion criteria and completed the follow-up period. At laparotomy, the median peritoneal cancer index (PCI) was 15 (range 3–35). The CRS procedure required a mean 8.3 surgical procedures per patient, and for 22 patients (66.6%), a complete cytoreduction was achieved. The mean hospital stay was 18days, and major morbidity developed in 21% of the patients. The operative mortality was 3%. When surgery ended, HIPEC was administered with cisplatin 75mg/m2for 60min at 43°C. During a median follow-up period of 73months, Kaplan–Meier analysis indicated a 5year OS of 30% (median 33.1months) and a PFS of 15.5% (median 18months). Multivariate analysis identified the completeness of cytoreduction (CC) score as the only significant factor independently influencing OS. Logistic regression for the clinicopathologic variables associated with complete cytoreduction (CC0) for patients with metachronous peritoneal spread from EC who underwent secondary CRS plus HIPEC identified the PCI as the only outcome predictor. Conclusions: For selected patients with peritoneal metastases from EC, when CRS leaves no residual disease, CRS plus HIPEC achieves outcomes approaching those for other indications such as colon and ovarian carcinoma.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29282600; info:eu-repo/semantics/altIdentifier/wos/WOS:000423533300015; volume:25; issue:3; firstpage:679; lastpage:687; numberofpages:9; journal:ANNALS OF SURGICAL ONCOLOGY; http://hdl.handle.net/11573/1117149Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85039858820

الإتاحة: https://doi.org/10.1245/s10434-017-6307-3Test
http://hdl.handle.net/11573/1117149Test

المؤلفون: Cornali, Tommaso, Sammartino, Paolo, Kopanakis, Nikolaos, Christopoulou, Athina, Framarino dei Malatesta, Marialuisa, Efstathiou, Elias, Spagnoli, Alessandra, Ciardi, Antonio, Biacchi, Daniele, Spiliotis, John

المصدر: Annals of Surgical Oncology ; volume 25, issue 3, page 679-687 ; ISSN 1068-9265 1534-4681

مصطلحات موضوعية: Oncology, Surgery

الإتاحة: https://doi.org/10.1245/s10434-017-6307-3Test

المؤلفون: Spiliotis, John, Iavazzo, Christos, Fotiou, Alexandros, Kopanakis, Nikolaos, Terra, Alexios, Efstathiou, Elias, Margari, Charalambia, Tsiatas, Marinos

المصدر: J Surg Oncol ; ISSN:1096-9098 ; Volume:123 ; Issue:2

مصطلحات موضوعية: HIPEC, intermediate, ovarian cancer, survival, upfront

الوصف: Newly diagnosed advanced-stage ovarian cancer patients are treated with neoadjuvant chemotherapy, primary or intermediate cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this study is to evaluate the optimal timing of cytoreduction plus HIPEC for advanced ovarian cancer patients.

العلاقة: https://doi.org/10.1002/jso.26280Test; https://pubmed.ncbi.nlm.nih.gov/33125733Test

الإتاحة: https://doi.org/10.1002/jso.26280Test
https://pubmed.ncbi.nlm.nih.gov/33125733Test

المؤلفون: Spiliotis, John, Iavazzo, Christos, Fotiou, Alexandros, Kopanakis, Nikolaos, Terra, Alexios, Efstathiou, Elias, Margari, Charalambia, Tsiatas, Marinos

المصدر: Journal of Surgical Oncology ; volume 123, issue 2, page 630-637 ; ISSN 0022-4790 1096-9098

الوصف: Background Newly diagnosed advanced‐stage ovarian cancer patients are treated with neoadjuvant chemotherapy, primary or intermediate cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this study is to evaluate the optimal timing of cytoreduction plus HIPEC for advanced ovarian cancer patients. Methods Advanced ovarian cancer patients treated with cytoreductive surgery plus HIPEC at three different hospitals between 2005 and 2019 were subgrouped regarding their time of management with cytoreduction plus HIPEC, upfront or intermediate. We retrospectively assessed the overall survival (OS), the progression‐free survival (PFS), and the disease‐free survival (DFS) of these groups. Results A total of 112 ovarian cancer patients were contained. Of whom, 47 patients were in the upfront group with 24 (51.1%) to be alive, while 65 patients were included in the intermediate group with 34 (52.3%) to be alive. OS (48 vs. 30 months) and DFS (42 vs. 20 months) indicated no significant difference. Although the same median PFS was observed in both groups (10 months), a higher mean PFS was observed in the upfront group (11.9 vs. 9 months, p = 0.023). Conclusion The treatment of advanced ovarian cancer patients with upfront cytoreductive surgery plus HIPEC is feasible with the same survival results. Further, larger prospective studies need to verify our results.

الإتاحة: https://doi.org/10.1002/jso.26280Test

المؤلفون: Spiliotis, John, Kopanakis, Nikolaos, Prodromidou, Anastasia, Raptis, Apostolos, Farmakis, Dimitrios, Efstathiou, Elias

المصدر: Surgical Innovation ; page 155335062095825 ; ISSN 1553-3506 1553-3514

مصطلحات موضوعية: Surgery

الإتاحة: https://doi.org/10.1177/1553350620958259Test

المؤلفون: Tzouma, Georgia Kopanakis, Nikolaos A. Tsakotos, George and Skandalakis, Panagiotis N. Filippou, Dimitrios

الوصف: The deep femoral artery (DFA) is the largest branch of the common femoral artery (CFA), supplying with its branches, the medial circumflex femoral artery (MCFA) and lateral circumflex femoral artery (LCFA), the thigh muscles, the hip joint, and the femur. Their anatomical variations have a great impact on both interventional and surgical procedures. The anterolateral thigh (ALT) flap, a versatile soft tissue with highly increasing use in reconstructive surgery, is noticeably influenced by this variability. A total of 25 articles were incorporated into the review. Studies conducted after the year 2009 were included. After the assessment of all studies included, we concluded that the DFA arises from the CFA with a varying site of origin, the posterolateral being the prevalent one found in 51.32% of cases. Of all cases studied, the MCFA and the LCFA most often originated from the DFA in 63.125% and 74.92%, respectively, but the CFA constitutes another frequent source of origin in 27% and 12.12% of cases, respectively. The descending branch of the lateral circumflex femoral artery (dLCFA) is the prominent pedicle in the ALT flap, originating from the LCFA in 83.55% of cases. However, the presence of an oblique lateral circumflex femoral artery (oLCFA) branch with changeable origination was observed. Knowledge of the anatomical variants in the deep femoral artery is imperative both for interventional radiologists and surgeons. Especially in reconstructive surgery, the possibility for different sources supplying the skin and the pedicle compel surgeons to acquire an awareness of this subject.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______2127::e474ae4f1d03f4b038d7c397c45c1ddfTest
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3190398Test

المؤلفون: Iavazzo, Christos R., Kopanakis, Nikolaos D., Spiliotis, John D.

المصدر: Journal of Surgical Oncology ; volume 118, issue 3, page 591-592 ; ISSN 0022-4790 1096-9098

الإتاحة: https://doi.org/10.1002/jso.25142Test

المؤلفون: Spiliotis, John D., Iavazzo, Christos, Kopanakis, Nikolaos D., Christopoulou, Athina

المصدر: Journal of the Turkish-German Gynecological Association; Dec2019, Vol. 20 Issue 4, p213-217, 5p, 2 Diagrams, 2 Charts

مصطلحات موضوعية: CANCER, CANCER chemotherapy, CANCER patients, COMPARATIVE studies, STATISTICAL correlation, DIAPHRAGM (Anatomy), DISEASES, MEDICAL records, MESENTERY, MORTALITY, MUSCLES, OVARIAN tumors, PELVIC floor, SURVIVAL analysis (Biometry), TIME, DISEASE relapse, RETROSPECTIVE studies, DESCRIPTIVE statistics, ACQUISITION of data methodology, CYTOREDUCTIVE surgery

مستخلص: Objective: To analyze the kind of ovarian cancer relapse by separating residual from recurrent disease and correlating them with patient survival. Material and Methods: This was a retrospective study of 200 women with ovarian carcinoma relapse between 2005 and 2017. Results: The main sites of residual disease included the great omentum, epiploic appendices, liver round ligament, gallbladder, and cervical/ vaginal stump. The median survival for women with residual disease treated with cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) + systemic chemotherapy was 38 months compared with the control group, which reached 23.8 months. The morbidity rates were 18% vs 7%, respectively, and the mortality rates were 2.5% vs 1.3%. The main sites of recurrent disease included the mesenterium, pelvic floor, diaphragm, and Glisson's capsule. Women with recurrent disease treated with CRS + HIPEC + systemic chemotherapy had median survival rates of 26 months vs 16 months in the control group. The morbidity rates were 22% vs 15%, respectively, and the mortality rates were 3.3% vs 0%. Conclusion: Patients undergoing secondary debulking plus HIPEC for ovarian carcinoma relapse have a different prognosis when compared with patients with residual and recurrent disease. A different prognosis is presented in women undergoing secondary debulking plus HIPEC for ovarian carcinoma relapse when comparing patients with residual and recurrent disease. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of the Turkish-German Gynecological Association is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)